Cellectis Total Assets

Latest as of June 2026: €267.37 Million EUR ≈ $312.58 Million USD

Cellectis total assets. Based on the latest financial reports, Cellectis (ALCLS) holds total assets worth €267.37 Million EUR (≈ $312.58 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Cellectis for the company's overall valuation and market capitalisation.

Total Assets of Cellectis (2002–2025)

Total assets of Cellectis from 2002 to 2025. This chart illustrates how Cellectis's total assets have evolved over time, based on quarterly financial data. See today's stock price for Cellectis for real-time trading data and today's change.

Cellectis - Asset Composition Analysis

Cellectis Total Assets Breakdown (December 2025)

Cellectis total assets breakdown as of December 2025. Cellectis's total assets of €267.37 Million consist of 72.8% current assets and 27.3% non-current assets.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€15.62 Million	19.0%
Accounts Receivable	€25.32 Million	7.8%
Inventory	€0.00	0.0%
Property, Plant & Equipment	€62.45 Million	19.2%
Intangible Assets	€535.00K	0.2%
Goodwill	€0.00	0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Cellectis's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ALCLS working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Cellectis's current assets represent 72.8% of total assets in 2025, an increase from 0.0% in 2002.
Cash Position: Cash and equivalents constituted 19.0% of total assets in 2025, down from 82.1% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2002.
Asset Diversification: The largest asset category is property, plant & equipment at 19.2% of total assets.

Cellectis Competitors by Total Assets

Key competitors of Cellectis based on total assets are shown below.

Company	Country	Total Assets
Samsung Biologics Co Ltd KO:207940	Korea	₩12.65 Trillion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	China	CN¥20.70 Billion
Immunovant Inc NASDAQ:IMVT	USA	$852.49 Million
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Amicus Therapeutics Inc NASDAQ:FOLD	USA	$949.87 Million

Cellectis - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.37	1.38	4.75
Quick Ratio	1.37	1.38	4.72
Cash Ratio	0.00	0.11	4.26
Working Capital	€49.46 Million	€63.21 Million	€186.25 Million

Cellectis - Advanced Valuation Insights

This section examines the relationship between Cellectis's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	7.81
Latest Market Cap to Assets Ratio	0.26
Asset Growth Rate (YoY)	-15.3%
Total Assets	€324.72 Million
Market Capitalization	$85.44 Million USD

Valuation Analysis

Below Book Valuation: The market values Cellectis's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Cellectis's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Cellectis (2002–2025)

The table below shows the annual total assets of Cellectis from 2002 to 2025.

Year	Total Assets	Change
2025-12-31	€324.72 Million ≈ $379.63 Million	-15.34%
2024-12-31	€383.54 Million ≈ $448.40 Million	+14.74%
2023-12-31	€334.27 Million ≈ $390.80 Million	+27.97%
2022-12-31	€261.22 Million ≈ $305.39 Million	-31.63%
2021-12-31	€382.08 Million ≈ $446.69 Million	-18.62%
2020-12-31	€469.47 Million ≈ $548.86 Million	+0.43%
2019-12-31	€467.47 Million ≈ $546.52 Million	-6.66%
2018-12-31	€500.84 Million ≈ $585.53 Million	+50.46%
2017-12-31	€332.88 Million ≈ $389.17 Million	+0.67%
2016-12-31	€330.68 Million ≈ $386.60 Million	-11.32%
2015-12-31	€372.88 Million ≈ $435.94 Million	+122.83%
2014-12-31	€167.34 Million ≈ $195.64 Million	+279.34%
2013-12-31	€44.11 Million ≈ $51.57 Million	-61.68%
2012-12-31	€115.11 Million ≈ $134.57 Million	-12.72%
2011-12-31	€131.89 Million ≈ $154.19 Million	+90.50%
2010-12-31	€69.23 Million ≈ $80.94 Million	-24.20%
2009-12-31	€91.34 Million ≈ $106.78 Million	+50.15%
2008-12-31	€60.83 Million ≈ $71.12 Million	+12.92%
2007-12-31	€53.87 Million ≈ $62.98 Million	+383.99%
2006-12-31	€11.13 Million ≈ $13.01 Million	-16.63%
2005-12-31	€13.35 Million ≈ $15.61 Million	+131.67%
2004-12-31	€5.76 Million ≈ $6.74 Million	-24.73%
2003-12-31	€7.66 Million ≈ $8.95 Million	-24.10%
2002-12-31	€10.09 Million ≈ $11.79 Million	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$85.44 Million

€73.08 Million EUR

Market Cap Rank

#19558 Global

#294 in France

Share Price

€1.01

Change (1 day)

-4.10%

52-Week Range

€0.94 - €4.57

All Time High

€40.90